APOE4drives transcriptional heterogeneity and maladaptive immunometabolic responses of astrocytes

• DOI: 10.1101/2023.02.06.527204
• Publication Date: 2023-02-07T06:55:17Z
• Authors: Sangderk Lee; Holden C. Williams; Amy A. Gorman; Nicholas A. Devanney; Douglas A. Harrison; Adeline E. Walsh; Danielle S. Goulding; Tony Tuck; James L. Schwartz; Diana J. Zajac; Shannon L. Macauley; Steven Estus; TCW Julia; Lance A. Johnson; Josh M. Morganti
• Keywords: 0301 basic medicine; 03 medical and health sciences; Article

SummaryApolipoprotein E4 (APOE4) is the strongest risk allele associated with the development of late onset Alzheimer’s disease (AD). Across the CNS, astrocytes are the predominant expressor ofAPOEwhile also being critical mediators of neuroinflammation and cerebral metabolism. APOE4 has been consistently linked with dysfunctional inflammation and metabolic processes, yet insights into the molecular constituents driving these responses remain unclear. Utilizing complementary approaches across humanized APOE mice and isogenic human iPSC astrocytes, we demonstrate that ApoE4 alters the astrocyte immunometabolic response to pro-inflammatory stimuli. Our findings show that ApoE4-expressing astrocytes acquire distinct transcriptional repertoires at single-cell and spatially-resolved domains, which are driven in-part by preferential utilization of the cRel transcription factor. Further, inhibiting cRel translocation in ApoE4 astrocytes abrogates inflammatory-induced glycolytic shifts and in tandem mitigates production of multiple pro-inflammatory cytokines. Altogether, our findings elucidate novel cellular underpinnings by which ApoE4 drives maladaptive immunometabolic responses of astrocytes.